Certara, Inc. (NASDAQ:CERT) Holdings Raised by Jane Street Group LLC

Jane Street Group LLC boosted its stake in Certara, Inc. (NASDAQ:CERT) by 2.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 147,393 shares of the company’s stock after buying an additional 3,732 shares during the period. Jane Street Group LLC owned 0.09% of Certara worth $1,726,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. State Street Corp increased its stake in shares of Certara by 3.4% during the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after acquiring an additional 122,411 shares during the period. Petrus Trust Company LTA acquired a new position in shares of Certara during the 3rd quarter valued at $994,000. Paloma Partners Management Co bought a new stake in shares of Certara in the 3rd quarter worth $413,000. 272 Capital LP acquired a new stake in shares of Certara in the third quarter valued at $177,000. Finally, Wasatch Advisors LP boosted its stake in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

CERT has been the topic of several research reports. Robert W. Baird dropped their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Finally, Barclays reduced their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Certara has a consensus rating of “Hold” and an average target price of $15.92.

Insider Transactions at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 9.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.39% of the stock is owned by insiders.

Certara Stock Down 0.4 %

Shares of NASDAQ:CERT opened at $10.70 on Thursday. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market cap of $1.72 billion, a PE ratio of -53.50, a price-to-earnings-growth ratio of 5.86 and a beta of 1.53. The firm has a 50 day simple moving average of $10.78 and a 200 day simple moving average of $12.29.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara’s revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.06 earnings per share. As a group, research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.